目的 探讨金水宝胶囊联合羧甲司坦治疗慢性阻塞性肺疾病稳定期的临床效果。方法 选取2017年1月-2018年1月唐山市丰润区人民医院收治的慢性阻塞性肺疾病稳定期患者120例，随机分成对照组（60例）和治疗组（60例）。对照组口服羧甲司坦片，2片/次，3次/d。治疗组在对照组基础上口服金水宝胶囊，3粒/次，3次/d。两组患者均治疗12周。观察两组患者临床疗效，同时比较治疗前后两组患者改良版英国医学研究委员会呼吸问卷（mMRC）评分、慢性阻塞性肺疾病患者自我评估测试（CAT）问卷评分、肺功能、及白介素-8（IL-8）、脂连素（APN）、总抗氧化能力（TAC）和8-羟基脱氧鸟苷（8-OHdG）水平。结果 治疗后，对照组和治疗组总有效率分别为83.3%和95.0%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者mMRC评分、CAT问卷评分均显著降低（P<0.05），且治疗组患者mMRC和CAT评分明显低于对照组（P<0.05）。治疗后，两组第1秒用力呼气容积（FEV1）/用力肺活量（FVC）、FEV1占预计值百分比（FEV1% pred）、一氧化碳弥散量（DLCO）/肺泡通气量（VA）和深吸气量（IC）/肺总量（TLC）值均显著升高（P<0.05），且治疗组患者肺功能明显高于对照组（P<0.05）。治疗后，两组血清IL-8、APN及8-OHdG浓度均显著降低（P<0.05），TAC显著升高（P<0.05），且治疗组IL-8、APN、TAC、8-OHdG水平明显优于对照组（P<0.05）。结论 金水宝胶囊联合羧甲司坦治疗慢性阻塞性肺疾病稳定期能有效缓解患者症状，改善肺功能，抑制炎症反应，增强机体抗氧化能力。

Objective Jinshuibao Capsules combined with carboxymethylsteine in treatment of stable phase of COPD. Methods Patients (120 cases) with stable phase of COPD in Fengrun District People's Hospital of Tangshan from January 2017 to January 2018 were randomly divided into control (60 cases) and treatment (60 cases) groups. Patients in the control group were po administered with Carbocysteine Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the mMRC scores, CAT scores, pulmonary function, IL-8, APN, TAC and 8-OHdG levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 83.3% and 95.0% respectively, and there were differences between two groups (P<0.05). After treatment, the mMRC scores and CAT scores in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the FEV1/FVC, FEV1%pred, DLCO/VA, and IC/TLC value in two groups were significantly increased (P<0.05), and the pulmonary function in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum concentration of IL-8, APN, and 8-OHdG in two groups was significantly decreased (P<0.05), TAC was significantly increased (P<0.05), and the IL-8, APN, TAC, and 8-OHdG levels in the treatment group were significantly lower than that in the control group (P<0.05). Conclusion Jinshuibao Capsules combined with carboxymethylsteine in treatment of stable chronic obstructive pulmonary disease can effectively relieve the symptoms, improve lung function, inhibit inflammatory reaction, and enhance the anti-oxidative activity.